NKTPD reported no revenue and a net loss of $458,253 for the six months ended June 30, 2026, versus $904,014 a year earlier. Operating expenses were $441,662, including $54,341 in research and development. Management does not expect significant revenue, including product sales, for at least the next two years, if ever; its oncology candidates remain in clinical development.
Cash was $17,144 at June 30, 2026; operating activities used $188,898, compared with $543,219 in the prior-year period. The company had a $3,834,528 accumulated deficit and a $250,000 note with $50,000 of accrued interest in default. It listed $355,000 of material future cash commitments for 2026. Management said these conditions raise substantial doubt about continuation as a going concern for at least one year from issuance.
After June 30, the board approved Philippe Deschamps as President, Chief Executive Officer, director and Chairman on July 14, 2026. The company completed a 25-for-1 reverse stock split on September 11, retrospectively adjusting presented share and per-share amounts.